Releaf

Our CEO, Tim Kirby sat down with SOMAÍ Pharmaceuticals CEO, Michael Sassano to discuss the future of the medical cannabis sector, in particular, how our strategic partnership is helping to generate exceptional patient outcomes in the UK. 70% of our patients are cannabis naive and some can be uncomfortable with flower and vaporising; that's why, with the help of SOMAÍ Pharmaceuticals we're working to open new demographics. SOMAÍ’s oils have been rigorously tested in independent studies and are regarded among the best in the world, with a purity and consistency comparable to that of extra virgin olive oil. This dedication to quality is sown in the clarity and consistency of their oils: Our partnership with SOMAÍ means that our patients will always benefit from treatment plans of guaranteed quality and consistency, which is why we have not only the most evolved and reliable supply chain in the UK market, but also why we are also the most trusted CBPM clinic in the UK. #patientcare #medicalcannabis #podcast Listen now: Youtube 📹 👉 https://lnkd.in/eNgimFNw Spotify 🎧 👉 https://lnkd.in/e_kpzum9

At Releaf, we see first-hand how personalised, expert guidance transforms patient outcomes in the #medicalcannabis sector. Specialised consultants don’t just guide treatments; they build bridges between complex #science and real-world application, ensuring patients feel confident and supported every step of the way. Led by our COO, Graham Woodward, Releaf’s Clinical Team receive comprehensive #training and participate in #onboarding programmes upon joining. Graham commented in a recent interview with Business of Cannabis | Europe: 'We have a mix of about 26 doctors on our team, including some of the most experienced cannabis prescribers in the country, as well as newer doctors just beginning their journey with cannabis prescribing. It’s critical to have people who are genuinely interested in learning—not just about cannabis, but about the conditions it can treat.' The dedication of our specialists to ongoing monitoring and individualised care is crucial in helping patients thrive, not just managing symptoms. We’re proud to play our part by providing tools and data that empower both patients and clinicians to make informed decisions; from our training programmes to our PROs (patient reported outcomes), a research project led by our Dr Hanna Gul, in which a comprehensive arrangement of questionnaires will sit within Releaf’s proprietary HealthTech platform to capture valuable insights into patient experiences, treatment efficacy, and overall outcomes. This data-driven approach not only enhances personalised care but also contributes to the broader understanding of medical cannabis therapy, supporting clinicians in refining their practices and improving patient well-being. With the right tools, training, and insights, we can transform lives and help unlock the full potential of medical cannabis for patients in need around the UK.

We are delighted to announce an extension to our exclusive supply agreement with Los-Angeles based heat not burn technology company – Omura . At Releaf, we put patients first in every decision, from our team, to the medication and products we offer. While #medicalcannabis has been legal in the UK since 2018, strict regulations govern its use. Due to health risks associated with combustion, smoking cannabis - even for medical purposes - remains illegal. This means flower patients must consume their prescription via a vaporiser. Omura shares our commitment to exceptional patient outcomes, directly addressing concerns tied to traditional vaporisers. Together, we’re focused on creating a superior, controlled experience for Releaf patients. Why we chose Omura: Dose-Controlled Experience: Omura’s Flowerstick System offers patients a consistent 0.12g dose of cannabis flower per stick, ensuring precise dosing and ensuring patients are in control of their experience. Proprietary Heat-Not-Burn Technology: Omura’s heat-not-burn technology optimises vaporisation, enhances the Entourage Effect, and ensures 99% cannabinoid extraction. By heating cannabis over a controlled range, the device avoids combustion, preserving the integrity of cannabinoids and terpenes. This technology delivers a smoother, more flavourful vapour and maximises therapeutic benefits. Ease of Use: Designed for simplicity, Omura’s device requires no packing, cleaning, or handling of sticky concentrates. Users simply insert a flowerstick and inhale, making it ideal for those new to cannabis or with limited dexterity. Portability: Omura’s compact, lightweight vaporiser fits conveniently into a pocket or bag, supporting patients’ daily routines with a long-lasting battery, ideal for on-the-go use without constant recharging. Discretion: Omura’s sleek, modern design emits minimal vapour and odour, making it the most discreet option for patients medicating in public or shared spaces. Its high-tech appearance resembles a gadget rather than a medical device. Sustainability: Omura is environmentally conscious; their flowersticks are made from FSC-certified pulp, making them sustainable and biodegradable—an eco-friendly choice over plastic-heavy alternatives. Our partnership with Omura underscores our commitment to providing the highest standard of care. By exclusively offering Omura’s products, we empower patients with safe, precise, and consistent ways to manage their treatment plans and experience the full therapeutic potential of medical cannabis. This collaboration aligns with our core mission of prioritising patient outcomes through innovative, patient-centred solutions, giving patients control of their health with the transformative benefits of medical cannabis. #patientcare #innovation

Our very own Rupa Shah and Graham Woodward had an insightful conversation with Business of Cannabis | Europe last week to talk about best practices for #compliance in the UK's #medicalcannabis sector. Our exceptional leadership team, including Rupa and Graham, have a stellar track record of leading rapid growth in complex, highly-regulated sectors. Meaning Releaf is able to expertly handle a difficult challenge: going to market in a fully compliant manner; a task that is not easy in this industry. 'Compliance is integrated into every part of our culture. [...] Everyone - whether in marketing, patient support, or any other team - understands that compliance is critical for gaining the trust of our patients.' This ethos is what drives our success and is what sets us part to lead the UK's #medicalcannabis sector. By embedding compliance into every aspect of our operations, both internal and external, we ensure that we are delivering the highest standards of care and trust to our patients. Thank you Business of Cannabis | Europe for hosting this discussion; it's through conversations like these that Releaf continues to raise the bar for #compliance and patient-focused innovation in the industry.

At Releaf, we have built an entire, patient-first ecosystem that simplifies and personalises your healthcare. Reading Charlotte’s post, we couldn’t agree more: up until Releaf’s launch in February 2024, the current UK CBPM landscape had been all over the place. Thankfully - this gave Releaf the opportunity to revolutionise it. So, how does Releaf do this? - Seamless Access for All Patients We understand patients’ previous frustrations: long waiting lists, unclear processes, and overwhelming bureaucracy. That’s why at Releaf, we invested £2M of our own money into our proprietary HealthTech platform - the only UK clinic to demonstrate this. From your virtual consultation through to tracking your prescription delivery, our platform is all-encompassing, allowing patients to access just the care they need. - Affordable, Transparent Pricing At Releaf, we operate with full transparency on pricing, so patients know what to expect upfront, with no hidden costs. That’s why we have a clear pricing page on our website: https://lnkd.in/eudk4aZJ We also have our innovative subscription plan, Releaf+, that gives patients the ability to book unlimited appointments with a consultant at a time that’s convenient for them, all included for just £39.99/month. - Changing the narrative This is essential for Releaf; one of the most powerful ways we do this is by sharing the stories of real patients that highlight the life-changing benefits of medical cannabis. We’re also committed to training our healthcare professionals to confidently prescribe CBPMs, empowering them with data and case studies, led by our COO Graham. - Inclusivity With virtual consultations and medication delivered straight to your door, a Releaf treatment plan is accessible to anyone eligible for it. - Changing the game Our data-driven approach with our PROs (patient reported outcomes), not only personalises patient care but also helps shape a better understanding of cannabis treatments for the wider community. We’re continuously building the perfect ecosystem for our patients and meanwhile transforming medical cannabis access in the UK.

Last week, our COO, Graham Woodward , sat down with Business of Cannabis | Europe to discuss expanding access to #medicalcannabis training for healthcare professionals in the UK, 6 years on from its legalisation in 2018. When asked about Releaf's approach to onboarding both new patients and new staff, Graham commented: 'There’s often a disparity between the potential patient demographic and the number of doctors available who are equipped to prescribe. While this can be a limiting factor, our proactive recruitment, training programs, and collaborative environment help us address this gap and ensure we’re continually growing our capacity to meet patient needs. We currently handle approximately 100 new patients a day, which is a capacity we deliberately maintain to ensure every patient receives quality care. We’ve scaled our operations to meet this level of demand.' Our success is evident; Releaf's combination of a detailed training and onboarding programme for clinicians, consequent highly trained specialists, lowest patient to support specialist ratio in the sector and £2M proprietary HealthTech platform, allows us handle approximately 100 new patients daily. Though it doesn't stop at 100 patients, we are uniquely positioned to meet the growing demand of the UK's #CBPM sector, all the while maintaining the highest healthcare standards and delivering exceptional patient outcomes. By strategically scaling our operations, our Clinical Team ensures that every patient receives the support they deserve - a testament to our leadership in the evolving CBPM sector. Read the full interview below.

What a great instalment to see in Charlotte Caldwell series this week! At Releaf, we know better than any other clinic that data-driven care in the #medicalcannabis field is a game changer. We always put our patients first and a huge part of this involves us tracking PROs (patient-reported outcomes), so we can understand what works for our patients and what doesn’t. It’s exactly this: 'Finding the perfect cannabis treatment isn’t “one size fits all” it’s a bit like dating but with less heartbreak and more spreadsheets.’ Releaf is proud to have the strictest prescribing guidelines in the sector and we continuously audit patient outcomes post-consultation; this ensures that there is continuity in the application of these guidelines, which helps to deliver an excellent improvement to our patients' quality of life. We also pride ourselves on the various types of data we collect. Our very own Dr Hanna Gul (MD, MRCP, MSc Oxon) Research and Quality Director, has utilised her 15 years of NHS experience coupled with her experience of supervising clinical trials and publishing manuscripts in peer-reviewed journals, to build a comprehensive arrangement of questionnaires that sit within Releaf’s proprietary HealthTech platform. These include standardised surveys like the EQ-5D, as well as disease-specific tools covering a range of conditions from MS to Parkinsons, Epliepsy, Fibromyalgia, Arthritis, Migraine, Menopause and more. As we continue to lead the movement of data-driven clinics, we remain committed to setting the highest standards in #patientcare and safety. By leveraging our state of the art technology, robust research techniques and continuous feedback from our patients, we’re shaping a future where CBPM treatments are not just effective but truly life-changing. At Releaf, every piece of data we collect serves one purpose: to ensure our patients receive the best, most personalised care possible. Together, we’re not just tracking outcomes; we’re redefining them!

As a vertically integrated clinic, this is something Releaf is well-equipped to talk about - thank you Charlotte, for bringing this topic into conversation! It’s no secret that UK patients have long been plagued with supply chain issues, that is why we made it our mission to ensure that patients will always receive their prescription to their door within 2-4 working days. You can read all about this guarantee in our Patient Charter: https://lnkd.in/dn3qPKnE But it’s not just the consistency of supply, it’s also the quality. Releaf has built strategic partnerships with Glass Pharms, the UK’s first domestically grown CBMP, entering into a ‘historic’ multimillion pound deal to secure a premium supply for our patients. Recently, we also announced our partnership with world-leading Cannabis oil producer, SOMAÍ Pharmaceuticals and Releaf patients are now enjoying top of the range oils - with the look and texture of extra virgin olive oil! Vertical integration does indeed streamline the supply chain and we also understand the need to provide our doctors with the scope to create tailored treatment plans that match a patients’ condition and lifestyle, that is why our formulary is carefully curated and built from trusted suppliers across X6 different regions. It’s not just our supply chain that reinforces us as the fastest-growing and most-trusted clinic in the UK, we’ve also built an ecosystem that is set to handle the rapidly expanding UK CBPM sector (an addressable market of approximately 3 million patients, based on a 3% adult penetration seen in mature markets), from the consistency and quality of supply, through to our unique, proprietary HealthTech platform. Within our platform, patients can manage their prescriptions, consultations, deliveries and access our dedicated Patient Support Team - all in one place. And we don’t stop there, we’re constantly building on patient feedback, funnelling over £700k p/a in salaries to developers who are driving improvement on the platform the user experience. We believe that managing every step of the process, from seed to patient care, allows us to deliver the most reliable, effective and personalised experience for our patients. With successful patient outcomes always as our end goal, we are constantly focused on responding to market demands and patient needs, keeping wait times low and accessibility high. Our vertically integrated approach ensures that we can deliver not just consistency, but also the highest level of care tailored to your individual needs. 

As a vertically integrated clinic, this is something Releaf is well-equipped to talk about - thank you Charlotte, for bringing this topic into conversation! It’s no secret that UK patients have long been plagued with supply chain issues, that is why we made it our mission to ensure that patients will always receive their prescription to their door within 2-4 working days. You can read all about this guarantee in our Patient Charter: https://lnkd.in/dn3qPKnE But it’s not just the consistency of supply, it’s also the quality. Releaf has built strategic partnerships with Glass Pharms, the UK’s first domestically grown CBMP, entering into a ‘historic’ multimillion pound deal to secure a premium supply for our patients. Recently, we also announced our partnership with world-leading Cannabis oil producer, SOMAÍ Pharmaceuticals and Releaf patients are now enjoying top of the range oils - with the look and texture of extra virgin olive oil! Vertical integration does indeed streamline the supply chain and we also understand the need to provide our doctors with the scope to create tailored treatment plans that match a patients’ condition and lifestyle, that is why our formulary is carefully curated and built from trusted suppliers across X6 different regions. It’s not just our supply chain that reinforces us as the fastest-growing and most-trusted clinic in the UK, we’ve also built an ecosystem that is set to handle the rapidly expanding UK CBPM sector (an addressable market of approximately 3 million patients, based on a 3% adult penetration seen in mature markets), from the consistency and quality of supply, through to our unique, proprietary HealthTech platform. Within our platform, patients can manage their prescriptions, consultations, deliveries and access our dedicated Patient Support Team - all in one place. And we don’t stop there, we’re constantly building on patient feedback, funnelling over £700k p/a in salaries to developers who are driving improvement on the platform the user experience. We believe that managing every step of the process, from seed to patient care, allows us to deliver the most reliable, effective and personalised experience for our patients. With successful patient outcomes always as our end goal, we are constantly focused on responding to market demands and patient needs, keeping wait times low and accessibility high. Our vertically integrated approach ensures that we can deliver not just consistency, but also the highest level of care tailored to your individual needs. 

Thank you, Charlotte, for shedding light on the complex issues surrounding patient access to medical cannabis in the UK. At Releaf, we’re committed to tackling these challenges by offering reliable, transparent and ethical patient support. Accessibility & reliable supply chains The current obstacles patients face - whether stock shortages, inconsistent quality, or inflated prices - can indeed be daunting - and outright unfair. At Releaf, we’ve prioritised strategic partnerships with trusted CBPM providers like Glass Pharms and Somai to ensure a steady supply of high-quality medications. This means our patients can rely on consistent access, knowing that every prescription will reach them within 2-4 working days, thanks to our Patient Charter. By making access reliable and consistent, we’re doing our part to ensure that prescriptions actually lead to life-changing treatment. Addressing the cost barrier We understand that cost is a major hurdle for many patients, and we’re committed to helping make CBPM treatment as affordable as possible.  While we only prescribe for adult patients, we recognise the financial strain CBPM costs place on families and individuals. At Releaf, we operate with full transparency on pricing, so patients know what to expect upfront, with no hidden costs. That's why we have a clear pricing page on our website: https://lnkd.in/eudk4aZJ We also have our innovative subscription plan, Releaf+, that gives patients the ability to book unlimited appointments with a consultant at a time that's convenient for them, all included for just £39.99/month. We firmly believe that patients should have a fair, transparent experience when it comes to pricing - and that’s a standard we uphold in every part of our service. Creating a professional, welcoming environment for patients As Charlotte mentioned, a growing number of patients new to cannabis are put off by the recreational image some brands portray. We completely condemn the likes of ‘F**k Around and Find Out’ and ‘Tyson 2.0’ - how can products like these be called medication? When they're clearly marketed towards a recreational market… At Releaf, we prioritise a professional approach, creating a safe and supportive space for patients new to CBPMs - in fact, 80% of our patient base are cannabis-naive and many share they were deterred from trying life-changing medication due to this recreationally focused imagery and messaging. We aim to be the industry gold standard, empowering patients to explore CBPMs without the gimmicks or brand ambassadors that can be so off-putting. Moving forwards? Releaf stands by a vision of CBPM care that supports and empowers every patient and we put our patients at the heart of all we do. Let’s bridge the gap between prescriptions and real patient access to life-changing #medicalcannabis treatment, creating an environment where CBPMs are a trusted option for all those who need it.